The ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute launch an Immuno-Oncology Research team at the Toulouse Oncopole Campus
June 2, 2016
The team will be part of the Cancer Research Center of Toulouse, backed by the “Institut Universitaire du Cancer” of Toulouse Oncopole
It will contribute to the international reputation of this unique medical research campus in Europe
The ‘Toulouse Cancer Santé’ Foundation is dedicated to medical research on cancer and has been recognized as a public-interest foundation by the French State since May 5, 2006
The Cancer Research Center of Toulouse (CRCT) is a joint research unit Inserm/University Toulouse III-Paul Sabatier, with some teams working under the CNRS’s label
The Cancer University Institute of Toulouse Oncopole (IUCT-O), dedicated exclusively to oncology patients, is a 300-bed hospital in association with the University Hospital of Toulouse and the Claudius Regaud
Institute (‘Centre de Lutte Contre le Cancer’)
Longstanding partners of the Toulouse Oncopole, Pierre Fabre Laboratories have defined oncology as their main target in drug research and development
Toulouse (France), Castres (France), June 2nd 2016 – The ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute, both major players on the Toulouse Oncopole campus, jointly announce the launch of a new research team within the Cancer Research Center of Toulouse (CRCT). This team, which will receive 5 years of funding in equal parts from the ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute, will be dedicated to research in immuno-oncology.
The team will be led by a world-class physician-scientist, specialized in translational medicine, with a proven expertise in immuno-oncology. The aim of translational medicine is to expedite therapeutic innovations by strengthening the connections between basic and clinical research.
To recruit this lead physician-scientist, a call for applications was launched on June 2nd, through advertisements in various scientific journals, including Nature, Science and the New England Journal of Medicine. The final decision on who will head the team will be made by the International Scientific Council of the Toulouse Cancer Santé Foundation and the Cancer University Institute of Toulouse (IUCT).
Through this initiative, the ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute aim at strengthening their collaboration to support research on the Toulouse Oncopole site, therefore contributing to the advance of knowledge in oncology and the discovery of new treatments for patients.
The recruitment of a prominent oncologist, with a combined expertise in translational
medicine and immuno-oncology, is a testament to the Foundation’s ambition for the Oncopole: attract and finance, here in Toulouse, the doctors and scientists who will make tomorrow’s discoveries, and elevate the Toulouse campus to a level of international excellence,” said Philippe Douste-Blazy, President of the ‘Toulouse Cancer Santé’ Foundation, on the day of this announcement.
The participation of Pierre Fabre in the creation of this team is consistent with the company’s decision of turning oncology into our lead pharmaceutical R&D target. Focusing on translational medicine and immuno-oncology, this team will work closely with our own research teams in both of these promising areas, as a way to boost the clinical evaluation of, and access to, new treatments for the benefit of patients, said Bertrand Parmentier, CEO of Pierre Fabre Laboratories. This investment also confirms our commitment to the development of the Oncopole and of Toulouse as an internationally recognized site for research in oncology.
Alongside chemotherapy, radiotherapy and surgery, immunotherapy has become a key element in the treatment of cancer and blood diseases. For a significant number of these pathologies, it will extend the control of the disease and even lead to cures that are unavailable today. The recruitment of an on-site international expert at the Oncopole will allow for a perfect structuring of this activity, said Michel Attal, Head of IUCT-Oncopole.
Recent clinical results obtained at IUCT-O and around the world show that after decades of relentless research, immunology begins to bear fruit in the treatment of certain cancers that have been, up to that point, difficult to cure. By hosting this new team, the CRCT is expanding its research workforce in immuno-oncology so that tomorrow, this therapeutic revolution can benefit to all patients, analyzed Dr. Jean-Jacques Fournié, Director of the Cancer Research Center of Toulouse.
I welcome the creation of this team of excellence, which contributes to the influence of the Toulouse Oncopole. This joint initiative from the IUCT-Oncopole, CRCT, ‘Toulouse Cancer Santé’ Foundation and Pierre Fabre Group is an illustration of the worldwide scientific ambition of the Oncopole. It strengthens Toulouse’s commitment to innovation in the life sciences and gives support to the scientific development of the campus. Prioritizing a stronger connection between basic and clinical research is a great step forward for patients, who will benefit more quickly from therapeutic innovations, commented Jean-Luc
Moudenc, Mayor of Toulouse.
Press Contact :
Valérie Roucoules - 01 49 10 83 84